A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an inquiry, and investors ought to keep that distinction nailed to the wall. Still, the allegations already laid out in the related securities class action are ugly enough that nobody holding QDEL should shrug them off.
Numbers That Refuse to Behave
The lawsuit describes serious alleged troubles with Savanna Respiratory Viral Panel 4, or RVP4, during its European rollout. Former employees cited in the complaint allegedly reported invalid-test rates between 10% and 30%, against an industry standard said to be roughly 1% to 2%. That is not a minor calibration nuisance if accurate. A test platform lives or dies on reliability. Labs do not have much patience for a machine that creates repeat work, uncertainty, or unhappy patients and clinicians.
The complaint also alleges that 60% to 80% of European customer feedback was negative and that about one in four instruments sold there needed replacement. Read those figures carefully: they are allegations from litigation, not verified operating statistics supplied by the company. But the basic investor concern is plain as day. A flagship system with a high replacement burden can chew through service resources, pressure margins, strain customer relationships, and make a commercial launch awfully hard to defend.
Manufacturing Is Where the Story Gets Meaner
What really sticks in my craw is the alleged manufacturing picture. According to the lawsuit, Savanna could not consistently meet FDA sensitivity requirements, while manufacturing yields fell sharply below internal targets. Former employees allegedly described scrap rates ranging from 50% to 80%. That is a brutal range. Even allowing for the fact that development and ramp-up periods can be messy, scrap at that level would suggest an operation burning material, time, and managerial attention at a pace no investor should casually accept.
Diagnostics is not a business where a polished presentation can substitute for execution. You need instruments that work, tests that perform, supply that shows up, and quality systems that hold together under regulatory scrutiny. If any of those gears grind, the commercial consequences can spread well beyond one product line. Sales teams lose credibility first. Then customers hesitate. Then the finance people start explaining why targets moved again. It is an old, unpleasant movie.
Allegations are not proof, but alleged product failures and alleged guidance gaps are precisely the combination that forces shareholders to ask harder questions about oversight.
The COVID Guidance Allegation Matters Too
The Savanna claims are only one side of the issue. The class action also alleges that QuidelOrtho doubled its endemic COVID-19 revenue guidance, moving from $150 million to $200 million up to a range of $200 million to $400 million, without supporting data. The complaint further alleges internal reports showed declining sales and growing inventory at the time.
Guidance is never sacred; management has to update its outlook when conditions change. But a big upward move in a mature, post-emergency COVID revenue category calls for a sturdy factual foundation. Investors can tolerate bad news more readily than they can tolerate the feeling that the dashboard was showing one thing inside the company while the public forecast implied another. That gap, if proven, is where litigation gets teeth and board-level oversight becomes more than a ceremonial phrase.
What Shareholders Should Separate
There are three separate layers here, and mashing them together creates more heat than light. First, KSF has announced an investigation focused on the conduct of officers and directors. Second, a securities class action has made specific allegations regarding product performance, manufacturing, customer feedback, and revenue guidance. Third, neither the investigation announcement nor the allegations themselves establish liability. Courts, evidence, company responses, and the actual record still matter. A lot.
That said, the questions are not frivolous just because they remain unproven. Long-term shareholders should be watching for clear disclosure around Savanna's performance, any remediation steps, manufacturing economics, customer retention, inventory management, and the assumptions behind revenue expectations. Vague reassurance will not cut it here. When the alleged trouble involves reliability, regulatory thresholds, and internal forecasts, precision is the only language worth listening to.
KSF notes that it is seeking information from people who may assist its inquiry, including long-term holders interested in discussing their rights. The firm’s announcement is part of a legal process, not an investment thesis by itself. But it does put a fresh spotlight on whether QuidelOrtho’s controls and oversight were strong enough when they mattered. For QDEL investors, that is the rub: the eventual debate may not be about whether a launch had problems, because plenty do. It may be about who knew what, when they knew it, and whether shareholders got the straight story.